Scientists create antibody ‘cocktail’ to fight deadly Lassa virus

The finding, made with the use of the Advanced Photon Source, shows a new way to exploit monoclonal antibodies to subvert the “shield” of the virus, potentially paving the way for new therapies.

Antibodies are a crucial ingredient in preventing infection for a wide variety of viruses. Scientists are frequently looking for new antibodies that could help fight viral infections. One deadly virus, the Lassa virus, infects hundreds of thousands of people annually, predominantly in Africa, causing its namesake: Lassa fever. There is as yet no approved vaccine or therapeutic against Lassa fever.

Now, however, scientists have identified three major monoclonal antibodies — artificial proteins that act like antibodies in the immune system — that can be used to potentially form the basis of a new vaccine that could save tens of thousands of lives a year.

The research team was led by Erica Ollmann Saphire, the president and CEO of the La Jolla Institute for Immunology (LJI), an organization dedicated to understanding and combating infectious diseases. Researchers from LJI used the bright X-ray beams produced by the Advanced Photon Source (APS), a U.S. Department of Energy (DOE) Office of Science user facility at DOE’s Argonne National Laboratory, to characterize three antibodies that target the Lassa virus’s protein structure. The antibodies were isolated from survivors of the disease.

“The work done at the APS allowed us to see what was happening on a molecular level.” — Haoyang Li, La Jolla Institute for Immunology

The result is a culmination of a 17-year project to look at the action of the Lassa virus and try to create a suite of biological molecules that could inhibit the virus’s ability to infect human cells.

“These antibodies are protective, but people weren’t sure why they were protective,” said Haoyang Li, a researcher at LJI and the first author on a paper based on the study. ​“The work done at the APS allowed us to see what was happening on a molecular level.”

“People may be familiar with monoclonal antibodies as a treatment for viruses such as the virus that causes COVID-19, but these kinds of antibodies can have positive effects on other viruses as well, like Lassa,” added Argonne physicist Naga Venugopalan.

According to Li, viruses such as Lassa are enveloped by a substance called glycoprotein. This glycoprotein is in turn equipped with a ​“glycan shield” made of carbohydrate molecules that typically both protects the virus from antibody attack and enables it to infect cells.

“Normally, antibodies cannot find a way to get through the glycan shield to get access to the protein to destroy the virus, but in our research we found that some of the antibodies could actually exploit the shield itself to reach the glycoprotein and neutralize the virus,” Li said.

The researchers strove to identify the virus’s weak spots, and they found that the most effective approach involved the use of a ​“cocktail” of the three antibodies to neutralize the virus. The antibody cocktail has been tested in nonhuman primates but is still awaiting federal approval for further study in humans. In the meantime, the researchers were interested in more fully understanding how the antibodies worked.

To do so, they used a combination of cryo-electron microscopy (cryo-EM) technology provided by LJI, and X-ray crystallography with X-rays provided by the APS. Partial structures of the three different antibodies and interaction of the glycoprotein complex with one of the antibodies were determined by X-ray crystallography. This information was used as an initial model when helping to fill out the atomic maps produced by the cryo-EM.

“X-ray crystallography provides us with a way to see the finer details of interactions between two proteins, namely, the side chain interactions,” Venugopalan said. ​“Information obtained from X-ray crystallography provides better clarity when fitting cryo-electron density maps.”

The ultimate goal would be to develop a vaccine that could drive the body into producing these antibodies naturally. ​“Because each of these antibodies in the cocktail can simultaneously bind to the glycoprotein, it creates the potential for a more effective treatment against Lassa virus than we have had to date.” Venugopalan said.

A paper based on the study was published in Science Translational Medicine on October 26, 2022.

About the Advanced Photon Source

The U. S. Department of Energy Office of Science’s Advanced Photon Source (APS) at Argonne National Laboratory is one of the world’s most productive X-ray light source facilities. The APS provides high-brightness X-ray beams to a diverse community of researchers in materials science, chemistry, condensed matter physics, the life and environmental sciences, and applied research. These X-rays are ideally suited for explorations of materials and biological structures; elemental distribution; chemical, magnetic, electronic states; and a wide range of technologically important engineering systems from batteries to fuel injector sprays, all of which are the foundations of our nation’s economic, technological, and physical well-being. Each year, more than 5,000 researchers use the APS to produce over 2,000 publications detailing impactful discoveries, and solve more vital biological protein structures than users of any other X-ray light source research facility. APS scientists and engineers innovate technology that is at the heart of advancing accelerator and light-source operations. This includes the insertion devices that produce extreme-brightness X-rays prized by researchers, lenses that focus the X-rays down to a few nanometers, instrumentation that maximizes the way the X-rays interact with samples being studied, and software that gathers and manages the massive quantity of data resulting from discovery research at the APS.

This research used resources of the Advanced Photon Source, a U.S. DOE Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract No. DE-AC02-06CH11357.

Argonne National Laboratory seeks solutions to pressing national problems in science and technology. The nation’s first national laboratory, Argonne conducts leading-edge basic and applied scientific research in virtually every scientific discipline. Argonne researchers work closely with researchers from hundreds of companies, universities, and federal, state and municipal agencies to help them solve their specific problems, advance America’s scientific leadership and prepare the nation for a better future. With employees from more than 60 nations, Argonne is managed by UChicago Argonne, LLC for the U.S. Department of Energy’s Office of Science.

The U.S. Department of Energy’s Office of Science is the single largest supporter of basic research in the physical sciences in the United States and is working to address some of the most pressing challenges of our time. For more information, visit https://​ener​gy​.gov/​s​c​ience.